Entelos, Inc. (LSE:ENTL), a leading life sciences company applying predictive technologies and "virtual humans" to find better drugs and more tailored health-related products announced today that Eli Lilly and Company (“Lilly”) has exercised its right to a perpetual license to Entelos’ DrugMatrix® database and additional customized report services from ToxFx™. Lilly will make a one-time payment to Entelos for a perpetual license and has the option for continued support. Financial terms were not disclosed.
“We are pleased that Lilly exercised its option to obtain a perpetual license to our powerful toxicogenomics database, customized reports, and safety reference systems,” commented James Karis, President and CEO of Entelos. “We look forward to continuing our support of Lilly and helping them to accelerate their adoption and integration of our cutting-edge predictive technologies within their research organization.”
The DrugMatrix database is a unique reference set of gene expression profiles for benchmark drugs and compounds that are linked to classic pharmacology, toxicology and clinical pathology measurements. It is populated with the comprehensive results of thousands of highly controlled and standardized experiments used to test for drug safety.
Profiles from over 630 different compounds from FDA approved drugs, drugs approved in Europe and Japan, withdrawn drugs, drugs in preclinical and clinical studies, biochemical standards and industrial and environmental toxicants are contained in DrugMatrix. Entelos customers using DrugMatrix can thus predict safety and toxicity liabilities of novel molecules using much shorter, faster, and more cost-effective gene expression studies as compared to traditional methods.